News & Publications

February 21, 2017 The HUB has a Cystic Fibrosis FIS assay article published in JoVE!

We are happy to announce that our article “Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients” has been published in the Journal of Visualized Experiments. Interested? Just follow the link! http://www.jove.com/video/55159/forskolin-induced-swelling-intestinal-organoids-an-vitro-assay-for

Read more

Posted by Hubrecht Organoid Technology

January 5, 2017 HUB and Dutch health insurance companies to validate use of organoids for Cystic Fybrosis

Utrecht, 4 January 2017 – Hubrecht Organoid Technology (HUB), and the health insurance companies CZ, Zilveren Kruis  and Menzis announced today that they will start a €3 million validation trial for use of HUB Organoid Technology to test if it can be used to determine the response of Cystic Fibrosis (CF) patients to new drug … Continue reading HUB and Dutch health insurance companies to validate use of organoids for Cystic Fybrosis

Read more

Posted by Hubrecht Organoid Technology

December 18, 2016 3D cancer cells library

A global effort to create a library of human cancer models using next-generation cell culture techniques launched last summer. The Human Cancer Models Initiative’s founding members include the Hubrecht Organoid Technology Foundation in Utrecht, the Netherlands; Cancer Research UK, in London; the National Cancer Institute (NCI) in Bethesda, Maryland; and the Wellcome Trust Sanger Institute … Continue reading 3D cancer cells library

Read more

Posted by Hubrecht Organoid Technology

October 9, 2016 Cystic fibrosis patients benefit from mini guts

A new test with ‘mini-guts’ or organoids can inform Cystic Fibrosis (CF) patients and their physicians whether they can benefit from a novel treatment against the disease. A major problem in the treatment of CF is the enormous genetic variability among patients. This means that for up to 50% of them it is unclear if … Continue reading Cystic fibrosis patients benefit from mini guts

Read more

Posted by Hubrecht Organoid Technology

July 12, 2016 International collaboration to create new cancer models to accelerate research

An international project to develop a large, globally accessible, bank of new cancer cell culture models for the research community launches today (Monday). The National Cancer Institute (NCI), Cancer Research UK, the Wellcome Trust Sanger Institute and the foundation Hubrecht Organoid Technology are joining forces to develop the Human Cancer Models Initiative (HCMI) which will … Continue reading International collaboration to create new cancer models to accelerate research

Read more

Posted by Hubrecht Organoid Technology

August 6, 2015 Galapagos licenses Organoid Technology from the HUB foundation for use in cystic fibrosis and IBD research

Galapagos NV (Euronext & NASDAQ: GLPG) announced on July 14th 2015 that it has entered into a licensing agreement with the HUB foundation for use of Organoid Technology for pre-clinical research in cystic fibrosis (CF) and inflammatory bowel disease (IBD). Read more

Read more

Posted by Hubrecht Organoid Technology

June 16, 2015 Organoid models of human and mouse ductal pancreatic cancer

Pancreatic cancer is one of the most lethal malignancies due to its late diagnosis and limited response to treatment. Tractable methods to identify and interrogate pathways involved in pancreatic tumorigenesis are urgently needed. We established organoid models from normal and neoplastic murine and human pancreas tissues. Pancreatic organoids can be rapidly generated from resected tumors … Continue reading Organoid models of human and mouse ductal pancreatic cancer

Read more

Posted by Hubrecht Organoid Technology

Long-term culture of genome-stable bipotent stem cells from adult human live

Despite the enormous replication potential of the human liver, there are currently no culture systems available that sustain hepatocyte replication and/or function in vitro. We have shown previously that single mouse Lgr5+ liver stem cells can be expanded as epithelial organoids in vitro and can be differentiated into functional hepatocytes in vitro and in vivo. … Continue reading Long-term culture of genome-stable bipotent stem cells from adult human live

Read more

Posted by Hubrecht Organoid Technology

In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection

BACKGROUND & AIMS: We previously established long-term, 3-dimensional culture of organoids from mouse tissues (intestine, stomach, pancreas, and liver) as well as human intestine and pancreas. Here we describe conditions required for long-term 3-dimensional culture of human gastric stem cells. The technology can be applied to study the epithelial response to infection with Helicobacter pylori. … Continue reading In vitro expansion of human gastric epithelial stem cells and their responses to bacterial infection

Read more

Posted by Hubrecht Organoid Technology

June 15, 2015 Prospective derivation of a living organoid biobank

3D organoid cultures derived from healthy and tumor tissue from colorectal cancer patients are used for a high throughput drug screen to identify genedrug associations that may facilitate personalized therapy. Read more here    

Read more

Posted by Hubrecht Organoid Technology